Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1999 • 8,737 citations

Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions

2007 • 2,003 citations

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

2006 • 1,766 citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

2004 • 1,624 citations

Chapter 2: The burden of HPV-related cancers

2006 • 1,374 citations

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

2007 • 1,287 citations

Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck

2001 • 931 citations

Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical Cancer

1999 • 495 citations

Model for Assessing Human Papillomavirus Vaccination Strategies

2007 • 484 citations

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

2006 • 480 citations

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

2006 • 480 citations

A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women

2004 • 415 citations

Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses

2006 • 286 citations

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

2007 • 236 citations

Impact of HPV infection in adolescent populations

2005 • 221 citations

Human Papillomavirus Prevalence and Type Distribution in Male Anogenital Sites and Semen

2007 • 175 citations

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

2002 • 167 citations

Acquisition and Persistence of Human Papillomavirus Infection in Younger Men: A Prospective Follow-up Study among Danish Soldiers

2005 • 166 citations

Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study

1996 • 163 citations

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

2007 • 160 citations

Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer

1997 • 138 citations

Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada

2006 • 133 citations

Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study

2002 • 127 citations

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

2007 • 86 citations

Vaccination as a prevention strategy for human papillomavirus-related diseases

2005 • 43 citations

Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Boostrix???)

2006 • 16 citations

27th Annual Meeting of the European Society for Pediatric Infectious Disease

2009 • 8 citations

Deleted Work

1955 • 0 citations